Immunicum AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Immunicum AB Receives Clearance to Start Second Clinical Study in 12 Liver Cancer Patients
Immunicum AB announced that the Company has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska University Hospital in Gothenburg. The liver cancer study will be completed in approximately two years and evaluates both the tolerability and efficacy of the treatment. Parallel to this, the Company will complete its ongoing phase I/II-study in renal cancer and intensify the planning of an upcoming phase II-trial.
Latest Developments for Immunicum AB
- Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from phase I/II-study in renal cell carcinoma
- Immunicum completes private placement and resolves rights issue bringing about SEK 100 mln
- Immunicum AB submits final report for phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data
- Immunicum AB reports promising preclinical results for its CD70 technology in adoptive immunotherapy
- Share this
- Digg this